This protocol targets patients with ocular myasthenia gravis who present with ophthalmoparesis (impaired eye movement) or ptosis (eyelid droop). Disease involvement is confined to the ocular muscles, and the treatment strategy is shaped by the severity and functional impact of these manifestations.
First-line management centres on anticholinesterase agents. The specific agent, dosing regimen, and clinical decision pathway are detailed in the full protocol.
The primary objective is resolution of ophthalmoparesis and ptosis.
DOI: 10.1212/WNL.0000000000011124
Ophthalmoparesis or ptosis in ocular MG that is not responding to anticholinesterase agents should be treated with immunosuppressant agents if symptoms are functionally limiting or troublesome to the patient.